Cargando…
Adenylosuccinic acid therapy ameliorates murine Duchenne Muscular Dystrophy
Arising from the ablation of the cytoskeletal protein dystrophin, Duchenne Muscular Dystrophy (DMD) is a debilitating and fatal skeletal muscle wasting disease underpinned by metabolic insufficiency. The inability to facilitate adequate energy production may impede calcium (Ca(2+)) buffering within,...
Autores principales: | Timpani, Cara A., Goodman, Craig A., Stathis, Christos G., White, Jason D., Mamchaoui, Kamel, Butler-Browne, Gillian, Gueven, Nuri, Hayes, Alan, Rybalka, Emma |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981178/ https://www.ncbi.nlm.nih.gov/pubmed/31980663 http://dx.doi.org/10.1038/s41598-020-57610-w |
Ejemplares similares
-
Nitric Oxide (NO) and Duchenne Muscular Dystrophy: NO Way to Go?
por: Timpani, Cara A., et al.
Publicado: (2020) -
Targeting Nrf2 for the treatment of Duchenne Muscular Dystrophy
por: Kourakis, Stephanie, et al.
Publicado: (2020) -
Metabogenic and Nutriceutical Approaches to Address Energy Dysregulation and Skeletal Muscle Wasting in Duchenne Muscular Dystrophy
por: Rybalka, Emma, et al.
Publicado: (2015) -
Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?
por: Kourakis, Stephanie, et al.
Publicado: (2021) -
Therapeutic strategies to address neuronal nitric oxide synthase deficiency and the loss of nitric oxide bioavailability in Duchenne Muscular Dystrophy
por: Timpani, Cara A., et al.
Publicado: (2017)